Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page
- Check4 days agoChange DetectedAn additional revision entry, v3.5.4, was added to the Study Record History, extending the version history after v3.5.3. The previous revision v3.5.3 has been removed from the current change set.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page’s footer/site revision label has been updated from v3.5.2 to v3.5.3, indicating a minor platform/version change without altering the clinical trial record shown.SummaryDifference0.1%

- Check32 days agoChange DetectedAdded Revision: v3.5.2 and deleted Revision: v3.5.0 in the study record history.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded Revision: v3.5.0; Removed Revision: v3.4.3 in the record history.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision history updated to add entry v3.4.3 and remove v3.4.2.SummaryDifference0.1%

- Check97 days agoChange DetectedThe page now shows that Revision: v3.4.2 was added and Revision: v3.4.1 was removed, as part of revision history updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.